Cardiff Oncology, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of solid tumor and hematologic cancers with significant unmet medical needs. The company focuses on its lead asset, onvansertib, a highly selective oral PLK1 inhibitor evaluated in combination with standard-of-care therapeutics; key clinical programs target RAS-mutated metastatic colorectal cancer (mCRC), metastatic castration-resistant prostate cancer (mCRPC) with abiraterone, metastatic pancreatic ductal adenocarcinoma (mPDAC) with biomarker selection, chronic myelomonocytic leukemia (CMML) as a single agent, medulloblastoma in combination with radiation, metastatic triple-negative breast cancer (mTNBC) with paclitaxel, small cell lung cancer (SCLC), and ovarian cancer with PARP inhibitors. Founded in 1999 and headquartered in San Diego, California, Cardiff Oncology operates primarily in the United States through clinical trials across multiple sites, with no subsidiaries or parent company relationships noted. Recent developments include the completion of enrollment in the randomized Phase 2 CRDF-004 trial evaluating onvansertib plus standard of care in first-line RAS-mutated mCRC, which reported positive data in Q3 2025 showing a 19% improvement in confirmed objective response rate (ORR) in the 30mg cohort versus control at the July 8 data cut-off, early progression-free survival (PFS) separation, dose-dependent tumor shrinkage, and good tolerability with no major unexpected toxicities; an update from this trial is expected in Q1 2026. In June 2025, the company appointed Dr. Roger Sidhu as Chief Medical Officer to guide late-stage development, announced positive Phase 1b data for onvansertib plus paclitaxel in mTNBC at ASCO 2025 demonstrating a 40% ORR, and secured a second U.S. patent (No. 12,263,173, expiring no earlier than 2043) covering onvansertib with bevacizumab in bevacizumab-naïve mCRC patients.
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
Cardiff Oncology: Market Dismisses Onvansertib's Potential In First-Line Colorectal Cancer
Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic Colorectal Cancer and Clinical Data on PLK1 Inhibitor Transcript
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
Head to Head Analysis: Cardiff Oncology (NASDAQ:CRDF) and BioStem Technologies (OTCMKTS:BSEM)
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.10 Consensus Target Price from Analysts
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference